Mariam Jafri

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 283 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 113 citations · Full text

Medicine, Oncology, Pharmacology +17

A Comprehensive Next Generation Sequencing–Based Genetic Testing Strategy To Improve Diagnosis of Inherited Pheochromocytoma and Paraganglioma

Eleanor Rattenberry, Lindsey Vialard, Anna C. Y. Yeung et al. · The Journal of Clinical Endocrinology & Metabolism · 2013 · 101 citations · Full text

Medicine, Genetics, Molecular Genetics +17

Germline Mutations in the<i>CDKN2B</i>Tumor Suppressor Gene Predispose to Renal Cell Carcinoma

Mariam Jafri, N. Wake, David B. Ascher et al. · Cancer Discovery · 2015 · 92 citations

Medicine, Genetics, Molecular Genetics +17

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17